These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34347212)

  • 1. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer.
    Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
    Cancer Causes Control; 2021 Dec; 32(12):1375-1384. PubMed ID: 34347212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer.
    Loroña NC; Othus M; Malone KE; Linden HM; Tang MC; Li CI
    Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):288-297. PubMed ID: 38019269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
    Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.
    Chen L; Chubak J; Boudreau DM; Barlow WE; Weiss NS; Li CI
    Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1603-1610. PubMed ID: 28807926
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
    Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
    Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
    Abubakar M; Sung H; Bcr D; Guida J; Tang TS; Pfeiffer RM; Yang XR
    Breast Cancer Res; 2018 Sep; 20(1):114. PubMed ID: 30227867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
    Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
    Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer.
    Baglia ML; Cook LS; Mei-Tzu C; Wiggins C; Hill D; Porter P; Li CI
    Int J Cancer; 2018 Oct; 143(8):1849-1857. PubMed ID: 29708591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
    van Maaren MC; de Munck L; Strobbe LJA; Sonke GS; Westenend PJ; Smidt ML; Poortmans PMP; Siesling S
    Int J Cancer; 2019 Jan; 144(2):263-272. PubMed ID: 30368776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between common risk factors and molecular subtypes in breast cancer patients.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years.
    Li CI; Daling JR; Tang MT; Haugen KL; Porter PL; Malone KE
    JAMA Intern Med; 2013 Sep; 173(17):1629-37. PubMed ID: 23921840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.